A bilayer solid composition comprising (a) an immediate release first layer
comprising an anti-allergic effective amount of desloratadine and at least
one pharmaceutically acceptable excipient and (b) a sustained release
second layer comprising an effective amount of a nasal decongestant, e.g.
pseudoephedrine sulfate and a pharmaceutically acceptable sustained
release agent wherein the composition contains less than about 2% of
desloratadine decomposition products is disclosed. A solid composition
comprising an anti-allergic effective amount of desloratadine and at least
one, and preferably two pharmaceutically acceptable antioxidants is also
disclosed.
